Bellevue Group AG, a Zurich-based boutique specializing in healthcare and biotechnology, reported its H1 2026 results, navigating a challenging environment marked by a rotation of capital into high-growth US technology stocks. This shift resulted in an 8.7% decrease in assets under management (AUM) to CHF 4.8 billion.
In response to these market pressures, the company implemented rigid cost controls, reducing operating expenses by 5.4% to CHF 21.5 million, which effectively countered a one-off non-cash impairment of CHF 0.6 million from a real estate restructuring. Despite the AUM decline, operating income improved by 4.4% to CHF 26.2 million, resulting in a net profit of CHF 1.8 million, up from CHF 0.2 million in the prior-year period.
CEO André Rüegg noted in the official report that while healthcare lagged technology in H1, signs of a trend reversal are emerging, with investors potentially shifting back toward defensive growth sectors with attractive, compressed valuations.
This performance reflects a broader theme in European wealth management, where managers face pressure from capital reallocations but seek to maintain profitability through disciplined, specialized strategies.